Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer.

The microenvironment is known to critically modulate tumor progression, yet its role in regulating treatment response is poorly understood. Here we found increased macrophage infiltration and cathepsin protease levels in mammary tumors following paclitaxel (Taxol) chemotherapy. Cathepsin-expressing macrophages protected against Taxol-induced tumor cell death in coculture, an effect fully reversed by cathepsin inhibition and mediated partially by cathepsins B and S. Macrophages were also found to protect against tumor cell death induced by additional chemotherapeutics, specifically etoposide and doxorubicin. Combining Taxol with cathepsin inhibition in vivo significantly enhanced efficacy against primary and metastatic tumors, supporting the therapeutic relevance of this effect. Additionally incorporating continuous low-dose cyclophosphamide dramatically impaired tumor growth and metastasis and improved survival. This study highlights the importance of integrated targeting of the tumor and its microenvironment and implicates macrophages and cathepsins in blunting chemotherapeutic response.

[1]  V. Gocheva,et al.  Deficiency of the macrophage growth factor CSF-1 disrupts pancreatic neuroendocrine tumor development , 2012, Oncogene.

[2]  Karin Jirström,et al.  Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. , 2011, Cancer discovery.

[3]  T. Reinheckel,et al.  Specialized roles for cysteine cathepsins in health and disease. , 2010, The Journal of clinical investigation.

[4]  L. Zitvogel,et al.  Desirable cell death during anticancer chemotherapy , 2010, Annals of the New York Academy of Sciences.

[5]  C. Peters,et al.  Deletion of cathepsin H perturbs angiogenic switching, vascularization and growth of tumors in a mouse model of pancreatic islet cell cancer , 2010, Biological chemistry.

[6]  R. Jain,et al.  Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation. , 2010, Cancer research.

[7]  P. Sorger,et al.  Dissecting Variability in Responses to Cancer Chemotherapy Through Systems Pharmacology , 2010, Clinical pharmacology and therapeutics.

[8]  C. Liao,et al.  Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment , 2010, Proceedings of the National Academy of Sciences.

[9]  Jeffrey W. Pollard,et al.  Macrophage Diversity Enhances Tumor Progression and Metastasis , 2010, Cell.

[10]  J. Joyce,et al.  IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. , 2010, Genes & development.

[11]  O. Vasiljeva,et al.  Synergistic antitumor effects of combined cathepsin B and cathepsin Z deficiencies on breast cancer progression and metastasis in mice , 2010, Proceedings of the National Academy of Sciences.

[12]  J. Pollard,et al.  Microenvironmental regulation of metastasis , 2009, Nature Reviews Cancer.

[13]  E. Alba,et al.  Maintenance treatment in metastatic breast cancer , 2008, Expert review of anticancer therapy.

[14]  R. Kerbel,et al.  Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. , 2008, Cancer cell.

[15]  M. Bogyo,et al.  Trial of the cysteine cathepsin inhibitor JPM-OEt on early and advanced mammary cancer stages in the MMTV-PyMT-transgenic mouse model , 2008, Biological chemistry.

[16]  T. Peretz,et al.  Cathepsin L Is Responsible for Processing and Activation of Proheparanase through Multiple Cleavages of a Linker Segment* , 2008, Journal of Biological Chemistry.

[17]  Dominique,et al.  Combining Agents that Target the Tumor Microenvironment Improves the Efficacy of Anticancer Therapy , 2008, Clinical Cancer Research.

[18]  C. Köhler.  Allograft inflammatory factor-1/Ionized calcium-binding adapter molecule 1 is specifically expressed by most subpopulations of macrophages and spermatids in testis , 2007, Cell and Tissue Research.

[19]  S. Abrams,et al.  Altered Immune Function during Long-Term Host-Tumor Interactions Can Be Modulated to Retard Autochthonous Neoplastic Growth1 , 2007, The Journal of Immunology.

[20]  D. Hanahan,et al.  Inhibition of cysteine cathepsin protease activity enhances chemotherapy regimens by decreasing tumor growth and invasiveness in a mouse model of multistage cancer. , 2007, Cancer research.

[21]  Bonnie F. Sloane,et al.  Cysteine cathepsins: multifunctional enzymes in cancer , 2006, Nature Reviews Cancer.

[22]  D. Hanahan,et al.  Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. , 2006, Genes & development.

[23]  Holger Gerhardt,et al.  Pericytes limit tumor cell metastasis. , 2006, The Journal of clinical investigation.

[24]  A. Nardin,et al.  Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma. , 2006, Current cancer drug targets.

[25]  Kristian Pietras,et al.  A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  D. Hicklin,et al.  A Comparative Analysis of Low-Dose Metronomic Cyclophosphamide Reveals Absent or Low-Grade Toxicity on Tissues Highly Sensitive to the Toxic Effects of Maximum Tolerated Dose Regimens , 2004, Cancer Research.

[27]  Robert S. Kerbel,et al.  The anti-angiogenic basis of metronomic chemotherapy , 2004, Nature Reviews Cancer.

[28]  D. Hanahan,et al.  Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. , 2004, Cancer cell.

[29]  R. Blasberg,et al.  A novel triple-modality reporter gene for whole-body fluorescent, bioluminescent, and nuclear noninvasive imaging , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[30]  Jeffrey W Pollard,et al.  Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. , 2003, The American journal of pathology.

[31]  Peter Bohlen,et al.  Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. , 2002, Cancer research.

[32]  J. Deussing,et al.  Cathepsin L deficiency as molecular defect of furless: hyperproliferation of keratinocytes and pertubation of hair follicle cycling , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[33]  H Lippert,et al.  Role of cathepsin B in intracellular trypsinogen activation and the onset of acute pancreatitis. , 2000, The Journal of clinical investigation.

[34]  A. Burlingame,et al.  Epoxide electrophiles as activity-dependent cysteine protease profiling and discovery tools. , 2000, Chemistry & biology.

[35]  T. Ley,et al.  Dipeptidyl peptidase I is required for the processing and activation of granzymes A and B in vivo. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[36]  G. Dranoff,et al.  Cathepsin S required for normal MHC class II peptide loading and germinal center development. , 1999, Immunity.

[37]  R. Straubinger,et al.  Novel Taxol Formulations: Preparation and Characterization of Taxol-Containing Liposomes , 1994, Pharmaceutical Research.

[38]  R. Cardiff,et al.  Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease , 1992, Molecular and cellular biology.

[39]  R. Cailleau,et al.  Tissue culture studies on pleural effusions from breast carcinoma patients. , 1974, Cancer research.

[40]  J. Joyce,et al.  Cysteine cathepsin proteases as pharmacological targets in cancer. , 2008, Trends in pharmacological sciences.

[41]  J. Gregg,et al.  Syngeneic mouse mammary carcinoma cell lines: Two closely related cell lines with divergent metastatic behavior , 2005, Clinical & Experimental Metastasis.

[42]  S Toba,et al.  Selective targeting of lysosomal cysteine proteases with radiolabeled electrophilic substrate analogs. , 2000, Chemistry & biology.